Back to search

University of Crete (UOC)

Ανάλυση των μεταγραφικών επιπέδων των γονιδίων ΤΡ53, ΤΡ63 και ΤΡ73 και των ισομορφών ΤΑp63, ΔΝp63, ΤΑp73 και ΔΝp73 στον καρκίνο της ουροδόχου κύστεως

Abstract

dc:description

The urinary bladder is a musculomembranous subperitoneal organ which functions asa reservoir for the urine in the human body. Urinary bladder cancer is the 11th mostcommon malignancy worldwide and the 4th most common among males in the UnitedStates, where 74,690 new cases will be diagnosed in 2014 alone. Smoking andoccupational exposure to aromatic amines are recognized as major risk factors for thedevelopment of the disease, followed by chronic urinary tract infection, Schistosomainfection in certain geographical regions, exposure to cyclophosphamide andradiotherapy to adjacent organs. It is estimated that 90-95% of bladder cancer casesare urothelial carcinomas, whereas the remaining 5-10% are mostly squamous cellcarcinomas and adenocarcinomas. Determination of tumor stage at diagnosis is crucialfor prognosis and patient management, as two major phenotypic variants of urothelialtumors with drastically different biological behavior have been recognized. Low-gradenon-muscle-invasive tumors, comprising approximately 80% of the cases, have limitedinvasive potential and come with favorable prognosis when treated early, althoughaccompanied by high recurrence rates. On the contrary, high-grade muscle-invasivetumors have very bad prognosis, with most of the patients developing life-threateningmetastases despite surgical resection and systemic therapy. The genetic alterationsunderlying the development of urothelial cancer include chromosomal aberrations,inactivating tumor-suppressor gene mutations and activation of oncogenes. FGFR3mutations are detected in more than 70% of non-muscle-invasive tumors, whereas p53is mutated in almost 50% of the muscle-invasive lesions.TP53 is the most extensively studied tumor-suppressor gene. Mutations in the TP53gene have been reported in the majority of human malignancies, suggesting asignificant contribution to the development and progression of human tumors. TwoTP53 homologs, TP63 and TP73, have recently been identified. Though highly similarwith p53 regarding genomic organization, both p63 and p73 utilize complexmechanisms to provide two major classes of protein isoforms with tumor-suppresive(TA-isoforms) or tumorigenic function (ΔN-isoforms). TAp63 and TAp73 exhibit p53-likefunction in terms of inducing apoptosis, whereas the N-terminally truncated ΔNp63 and ΔNp73 act as dominant negative inhibitors of both wild-type p53 protein and therespective TA-isoforms. Both TP63 and TP73 are rarely mutated in human tumors,whereas their deletion from mice results in various developmental and neurologicalabnormalities rather than the development of malignant lesions. Overall, it is evidentthat the two TP53 homologs are not to be considered as classic tumor-suppressorgenes.The objective of this PhD thesis was to determine the expression levels of the threep53 family genes (TP53, TP63, TP73) and the TP63 and TP73 TA and ΔN isoforms inbladder tumors and to evaluate any alterations in their expression patterns that mightbe associated with the development and progression of urothelial malignancies. Theexpression analysis was performed in a set of 30 urothelial tumors, matched withnormal tissues, which were obtained from bladder cancer patients who underwentsurgical resection of bladder tumor.Expression analysis revealed elevated p53, p63 and p73 mRNA levels in 47.0%, 40.0%and 43.0% of the samples, respectively. p53, p63 and p73 exhibited a 1.9-fold, 3.0-foldand 2.0-fold overexpression in tumor specimens compared with the normal samples,respectively. In the normal bladder epithelium, all members of the p53 gene familywere co-expressed (p <0.001). However, in malignant urothelium, only the positive coexpressionbetween p63 and p73 was maintained (p=0.008). Statistical analysisrevealed that p53 was up-regulated in non-muscle-invasive (pTa-T1) tumors comparedwith muscle-invasive (pT2-T4) ones (p=0.047). Significantly higher p63 mRNA levelswere measured in malignant samples from patients > 75 years of age versus youngerpatients (p=0.022) and from patients with disease relapse compared with cancer-freepatients (p=0.045). p63 expression significantly deviated from the normal pattern inpapillary versus non-papillary lesions (p=0.026). p73 overexpression was observed inGrade III tumors compared with Grade II tumors, in patients presenting with one-sitelesions (p=0.040).Also, elevated TAp63, ΔNp63, TAp73 and ΔNp73 mRNA levels were measured in 33.0%,50.0%, 40.0% and 37.0% of the samples, respectively. TAp63, ΔNp63, TAp73 andΔNp73 exhibited a 2.9-fold, 3.2-fold, 1.7-fold and 3.3-fold overexpression in tumorspecimens compared with the normal samples, respectively. Tumor-specific TAp63expression was detected in 3 cases, while TAp63 was expressed only in normal tissuein 4 cases. Tumor-specific ΔNp73 expression was detected in 7 cases, while ΔNp73 wasexpressed only in normal tissue in 4 cases. ΔNp73 was also not expressed in 3 tissuepairs. The ΔNp63/TAp63 isoform ratio shifted 1.1-fold in favor of ΔΝp63, and theΔNp73/TAp73 isoform ratio shifted 2.0-fold in favor of ΔΝp73 from normal to tumorspecimens. In normal urothelium TAp73 was co-expressed with ΔNp73 (p=0.003). Inthe malignant bladder epithelium ΔNp63 negatively correlated with TAp73 (p=0.006).Statistical analysis revealed that ΔΝp63 was up-regulated in tumor samples frombladder cancer patients > 75 years old versus younger ones (p=0.026), in non-muscleinvasive(pTa-T1) tumors versus muscle-invasive ones (pT2-T4) (p=0.019) and inpatients who received BCG treatment versus those who were treated with cystectomy(p=0.045). TAp73 mRNA levels were increased in patients with papillary tumorscompared with those with non-papillary ones (p=0.006) and in current smokerscompared with non-smokers and ex-smokers combined (p=0.020). Our results indicate that expression of all TP53 family members deviate from thenormal pattern in bladder tumors. p63 overexpression is associated with a lessaggressive tumor phenotype, whereas p73 up-regulation correlates with anunfavorable patient outcome. We also provide evidence that p63 and p73 exert theircontribution to the malignant transformation of the bladder epithelium independentlyof p53. In addition, our results support an anti-invasive role for ΔNp63 in urothelialcancers and a potentially protective effect of TAp73 on bladder epithelium. Finally, weprovide evidence for epigenetic regulation of p63 and p73 isoforms expression innormal and malignant urothelium.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadogianni, Danai
  • Παπαδογιάννη, Δανάη

Subjects

dc:subject × 20

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41575

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadogianni, Danai; Παπαδογιάννη, Δανάη. Ανάλυση των μεταγραφικών επιπέδων των γονιδίων ΤΡ53, ΤΡ63 και ΤΡ73 και των ισομορφών ΤΑp63, ΔΝp63, ΤΑp73 και ΔΝp73 στον καρκίνο της ουροδόχου κύστεως. University of Crete (UOC), 2014. http://hdl.handle.net/10442/hedi/41575